Experts Discuss the RCC Landscape and Available Therapy for Patients

home / case-based-roundtable-series / experts-discuss-the-rcc-landscape-and-available-therapy-for-patients

This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.

Key Considerations for Selecting Frontline Therapy in Advanced RCC

Key Considerations for Selecting Frontline Therapy in Advanced RCC

Naomi Haas, MD
June 24th 2022

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.

Recommendations for Treating Non–Clear Cell RCC

Recommendations for Treating Non–Clear Cell RCC

Pedro C. Barata, MD, MSc
August 19th 2022

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.

Ongoing Trials Investigate Intensified Frontline Therapy for RCC

Ongoing Trials Investigate Intensified Frontline Therapy for RCC

Bradley McGregor, MD
September 26th 2022

Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.

Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC

Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC

Manojkumar Bupathi, MD, MS
October 17th 2022

Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.

Current and Potential Second-Line Therapies Following IO/TKI in RCC

Current and Potential Second-Line Therapies Following IO/TKI in RCC

Bradley McGregor, MD
November 11th 2022

Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.

Factors Influencing Frontline Therapy Options for Favorable-Risk RCC

Factors Influencing Frontline Therapy Options for Favorable-Risk RCC

Naomi Haas, MD
January 9th 2023

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.